Adaptive Biotechnologies CEO Chad Robins on that crazy IPO and working with his older brother

Adaptive Biotechnologies Corp. debuted Thursday with a bang, with the stock price doubling on the first day. By Friday afternoon, the stock had climbed another 11%.

Investors seem to be keen on the company’s ADPT, +19.85% vision: That the future of disease diagnostics and treatment lies in the immune system — specifically, the adaptive immune system.

Read: Adaptive Biotechnologies IPO: Five things to know

The adaptive immune system is made up of immune cells called T cells and B cells that can detect when something foreign enters the body, whether it’s bacteria, a virus or cell mutation.

>>> Original Source <<<